Latent tuberculosis: Which test in which situation?

Swiss Medical Weekly

Volumn 138, Issue 3-4, 2008, Pages 31-37

  Zellweger, Jean Pierre ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Contact investigations; Interferon gamma assays; Latent tuberculosis infection; Tuberculin skin test; Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

COST EFFECTIVENESS ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE DEFICIENCY; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; REVIEW; RISK FACTOR; SCREENING TEST; T LYMPHOCYTE; TUBERCULIN TEST;

EID: 38749101991     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060-7.
2. Radhakrishna S, Frieden TR, Subramani R. Association of initial tuberculin sensitivity, age and sex with the incidence of tuberculosis in south India: a 15-year follow-up. Int J Tuberc Lung Dis. 2003;7(11):1083-91.
3. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med. 2007;167(4):335-42.
4. Moran-Mendoza O, Marion SA, Elwood K, Patrick DM, FitzGerald JM. Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts. Int J Tuberc Lung Dis. 2007;11(9):1014-20.
5. Sutherland I, Svandova E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. Tubercle. 1982;63:255-68.
6. Jackson-Sillah D, Hill PC, Fox A, et al. Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia. Trans R Soc Trop Med Hyg. 2007;101(6):594-601.
7. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221-S247.
8. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis : five years of follow-up in the IUAT trial. Bull Wld Hlth Org. 1982;60:555-64.
9. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res. 1970;17(Karger,Basel/N.Y:28-106.
10. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J. 2005;26(3):465-73.
11. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos : a final report of the Bethel Isoniazid studies. Am Rev Respir Dis. 1979;119:827-30.
12. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007;131(6):1898-906.
13. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2007;11(1):16-26.
14. Rothel JS, Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? Expert Rev Anti Infect Ther. 2005;3(6):981-93.
15. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2006;174(7):736-42.
16. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099-104.
17. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis. 2005;24(8):529-36.
18. Diel R, Ernst M, Doscher G, et al. Avoiding the effect of BCG-vaccination in detecting MTB infection with a blood test. Eur Respir J. 2006;28:16-23.
19. Arend SM, Thijsen SF, Leyten EM, et al. Comparison of Two Interferon-Gamma Assays and Tuberculin Skin Test for Tracing TB Contacts. Am J Respir Crit Care Med. 2006;175(6):618-27.
20. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4(12):761-76.
21. Pai M, Lewinsohn DM. Interferon-gamma assays for tuberculosis: is anergy the Achilles' heel? Am J Respir Crit Care Med. 2005;172(5):519-21.
22. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J. 2006;28:24-30.
23. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 Infection on T-Cell-based and Skin Test Detection of Tuberculosis Infection. Am J Respir Crit Care Med. 2007;175(5):514-20.
24. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent Tuberculosis in HIV positive, diagnosed by the M. Tuberculosis Specific Interferon Gamma test. Respir Res. 2006;7(1):56.
25. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell based test for detection of TB infection among immunocompromised patients. Eur Respir J. 2006;28:31-4.
26. Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol. 2006;doi 10.2215.
27. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax. 2006;61(7):616-20.
28. Nakaoka H, Lawson L, Squire SB, et al. Risk for tuberculosis among children. Emerg Infect Dis. 2006;12(9):1383-8.
29. Hill PC, Brookes RH, Fox A, et al. Surprisingly High Specificity of the PPD Skin Test for M. tuberculosis Infection from Recent Exposure in The Gambia. PLoS ONE 2006;1:e68.
30. Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis. 2007;45(3):322-8.
31. Richeldi L, Ewer K, Losi M, et al. T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. Pediatrics. 2007;119(1):e1-e5.
32. Dogra S, Narang P, Mendiratta DK, et al. Comparison of a whole blood interferon-gamma assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. J Infect. 2006;54:267-76.
33. Pai M, Dogra S, Narang P. Interferon-gamma release assays in children - No better than tuberculin skin testing: Response to Ranganathan S et al. J Infect. 2006;54(4):414-5.
34. Ranganathan S, Connell T, Curtis N. Interferon-gamma release assays in children - No better than tuberculin skin testing? J Infect. 2006;54(4):412-3.
35. Pai M, Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis? Clin Infect Dis. 2007;44(1):74-7.
36. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet. 2001;357(9273):2017-21.
37. Ewer K, Deeks T, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361(9364):1168-73.
38. Zellweger JP, Zellweger A, Ansermet S, de Senarclens B, Wrighton-Smith P. Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis. 2005;9(11):1242-7.
39. Leyten EM, Prins C, Bossink AW, et al. Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-(gamma) assay. Eur Respir J. 2007;29(6):1212-6.
40. Richeldi L, Ewer K, Losi M, Roversi P, Fabbri LM, Lalvani A. Repeated tuberculin testing does not induce false positive ELISPOT results. Thorax. 2006;61(2):180.
41. Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-(gamma) responses at 6 weeks following tuberculin skin testing. Eur Respir J. 2007;29(6):1282-3.
42. Mazurek GH, Weis SE, Moonan PK, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis. 2007;45(7):837-45.
43. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis. 2004;38(5):754-6.
44. Chee CB, Khinmar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent Tuberculosis Infection Treatment and T-Cell Responses to Mycobacterium tuberculosis-specific Antigens. Am J Respir Crit Care Med. 2007;175(3):282-7.
45. Dheda K, Pooran A, Pai M, et al. Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. J Infect. 2007;55:169-73.
46. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006;174(7):831-9.
47. Hill PC, Brookes RH, Fox A, et al. Longitudinal Assessment of an ELISPOT Test for Mycobacterium tuberculosis Infection. PLoS Med. 2007;4(6):e192.
48. Pai M, O'Brien R. Serial Testing for Tuberculosis: Can We Make Sense of T Cell Assay Conversions and Reversions? PLoS Med. 2007;4(6):e208.
49. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med. 2007;13(5):175-82.
50. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol. 2002;40(2):704-6.
51. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis. 2007;7(6):428-38.
52. Ferrara G, Losi M, Meacci M, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2005;172(5):631-5.
53. Beffa P, Zellweger A, Jaussens JP, Wrighton-Smith P, Zellweger JP. Indeterminate test results of T-SPOT.TB perfomed under routine field conditions. Eur Respir J. Published online before print Dec 2007 dei:doi:10.1183/09031936. 00117207.
54. Doherty TM, Demissie A, Menzies D, Andersen P, Rook G, Zumla A. Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J Immunol Methods. 2005;298(1-2):129-41.
55. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006;367(9519):1328-34.
56. Mahomed H, Hughes EJ, Hawkridge T, et al. Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. Int J Tuberc Lung Dis. 2006;10(3):310-6.
57. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146(5):340-54.
58. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR. 2005;54(RR-15):1-48.
59. Test de détection de la production d'interféron gamma pour le diagnostic des infections tuberculeuses. Haute Autorité de Santé, editor. 2006. Saint-Denis La Plaine, Collège de la Haute Autorité de Santé. Ref Type: Report.
60. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J. 2006;28:45-50.
61. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Royal College of Physicians, editor. 2006. London. Ref Type: Report.
62. Ligue Pulmonaire Suisse. Manuel de la tuberculose. 2nd ed. Berne: Ligue Pulmonaire Suisse, www.tbinfo.ch; 2007.
63. Starke JR. Interferon-gamma release assays for diagnosis of tuberculosis infection in children. Pediatr Infect Dis J. 2006;25(10):941-2.
64. Lalvani A, Millington KA. T cell-based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis. 2007;20(3):264-71.
65. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology. (Oxford) 2005;44(6):714-20.
66. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122-7.
67. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with rumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-5.
68. Cobelens FG. Tuberculosis risks for health care workers in Africa. Clin Infect Dis. 2007;44(3):324-6.
69. De Vries G, Sebek MM, Lambregts-van Weezenbeek CS. Health care workers with tuberculosis infected during work in the Netherlands. Eur Respir J. 2006;28:1216-21.
70. Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis. 2005;40(2):211-7.
71. Nienhaus A, Schablon A, Back CL, Siano B, Diel R. Evaluation of the interferon-gamma release assay in healthcare workers. Int Arch Occup Environ Health 2007;DOI 10.1007/s00420-007-0212-1.
72. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med. 2006;174(3):349-55.
73. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of Interferon-(gamma) Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany. Chest. 2007;131(5):1424-34.
74. Diel R, Wrighton-Smith P, Zellweger JP. Cost-effectiveness of Interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J. 2007;30(2):321-32.